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PHypertrophic Cardiomyopathy
yosin Binding Protein C Mutations and
ompound Heterozygosity in Hypertrophic Cardiomyopathy
ara L. Van Driest, BA,* Vlad C. Vasile, MD,* Steve R. Ommen, MD, FACC,† Melissa L. Will, BS,*
. Jamil Tajik, MD, FACC,†‡ Bernard J. Gersh, MD, FACC,† Michael J. Ackerman, MD, PHD, FACC*†‡
ochester, Minnesota
OBJECTIVES We sought to determine the frequency and phenotype of mutations in myosin binding protein
C (MYBPC3) in a large outpatient cohort of patients with hypertrophic cardiomyopathy
(HCM) seen at our tertiary referral center.
BACKGROUND Mutations in MYBPC3 are one of the most frequent genetic causes of HCM and have been
associated with variable onset of disease and prognosis. However, the frequency of mutations and
associated clinical presentation have not been established in a large, unrelated cohort of patients.
METHODS Using deoxyribonucleic acid from 389 unrelated patients with HCM, each protein coding
exon of MYBPC3 was analyzed for mutations by polymerase chain reaction, denaturing
high-performance liquid chromatography, and direct deoxyribonucleic acid sequencing.
Clinical data were extracted from patient records blinded to patient genotype.
RESULTS Of 389 patients with HCM, 71 (18%) had mutations in MYBPC3. In all, 46 mutations were
identified, 33 of which were novel (72%). Patients with MYBPC3 mutations did not differ
significantly from patients with thick filament-HCM, thin filament-HCM, or genotype-
negative HCM with respect to age at diagnosis, degree of hypertrophy, incidence of
myectomy, or family history of HCM or sudden death. Patients with multiple mutations (n
 10, 2.6%) had the most severe disease presentation.
CONCLUSIONS This study defines the frequency and associated phenotype for MYBPC3 and/or multiple
mutations in HCM in the largest cohort to date. In this cohort, unrelated patients with
MYBPC3-HCM virtually mimicked the phenotype of those with mutations in the beta-
myosin heavy chain. Patients with multiple mutations had the most severe
phenotype. (J Am Coll Cardiol 2004;44:1903–10) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.045Cardiology Foundation
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pypertrophic cardiomyopathy (HCM), clinically defined as
hickening of the myocardial wall in the absence of any other
ause for left ventricular hypertrophy, affects 1 in 500 individ-
als and is the leading cause of sudden cardiac death (SCD) in
he young (1). Genetic causes are diverse, with over 200
ublished disease-associated mutations scattered among 10
arcomeric genes (2). One of the most common genetic causes
or HCM in many populations studied involves mutations in
YBPC3, the gene encoding myosin binding protein C (3–6).
ver 60 HCM-causing mutations in MYBPC3 have been
eported. Unlike the other sarcomeric genes, where missense
utations overwhelmingly predominate, approximately one-
hird of all MYBPC3 mutations are single amino acid substi-
utions (i.e., missense mutations), approximately one-third are
rameshift mutations, and the remaining mutations cause
remature stop codons, in-frame insertions or deletions, or
ffect splicing (4).
From the *Department of Molecular Pharmacology and Experimental Therapeu-
ics; †Department of Internal Medicine, Division of Cardiovascular Medicine; and
Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiol-
gy, Mayo Clinic College of Medicine, Rochester, Minnesota. Dr. Ackerman is
upported by the Mayo Foundation, a Clinical Scientist Development Award from
he Doris Duke Charitable Foundation, an Established Investigator Award from the
merican Heart Association, and the National Institutes of Health (HD42569).s
Manuscript received April 23, 2004; revised manuscript received June 25, 2004,
ccepted July 28, 2004.Several studies have sought to define the phenotype
ssociated with mutations in MYBPC3. Variability in the
nset of disease and prognosis have been observed, but, in
eneral, from the findings of studies of large families and
pecific patient subgroups, MYBPC3-HCM has been asso-
iated with later onset, less hypertrophy, lower penetrance,
nd a better prognosis than HCM caused by mutations in
he beta-myosin heavy chain gene (MYH7) (7–10). These
ata suggested that MYBPC3 mutations may be the pre-
ominant genetic substrate for HCM in elderly patients,
mong whom the natural history is generally favorable (11).
n addition, it has been suggested that patients with protein
runcations in MYBPC3 manifested HCM earlier in life and
equired more invasive therapy than those harboring either
issense or in-frame mutations (12). We sought to deter-
ine the frequency of MYBPC3 mutations in a large cohort
f unrelated patients and establish genotype-phenotype
orrelations for this outpatient tertiary referral center.
ETHODS
ohort. Between April 1997 and December 2001, 389
nrelated patients who were evaluated and diagnosed at
ayo Clinic with unequivocal and unexplained HCM
rovided written informed consent and were enrolled in
arcomeric genetic testing. Patients were eligible for enroll-
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MYBPC3 and Compound Heterozygosity in HCM November 2, 2004:1903–10ent on the basis of: 1) being seen and evaluated in the
CM clinic; 2) having an unequivocal diagnosis of HCM;
nd 3) being the first family member seen during this time
eriod. By definition, each subject met the clinical diagnos-
ic criteria for HCM by having a maximum left ventricular
all thickness (LVWT) 13 mm in the absence of another
onfounding diagnosis. Purgene deoxyribonucleic acid
DNA) extraction kits (Gentra, Inc., Minneapolis, Minne-
ota) were used to extract total genomic DNA for subse-
uent mutational analysis. This single-institution cohort
as genotyped previously for mutations in genes encoding
he sarcomeric proteins comprising the thick filament
MYH7 and the regulatory and essential light chains [MYL2
nd MYL3]) and the thin filament (troponin-T [TNNT2],
roponin-I [TNNI3], alpha-tropomyosin [TPM1], and
lpha-actin [ACTC]) (13,14).
utation detection. Polymerase chain reaction primers
ere designed to amplify all exons and flanking intronic
equences for each of the 34 protein-coding exons of
YBPC3. Primers and methods are available upon re-
uest. Each patient’s DNA sample was amplified for each
xon, and amplicons were analyzed for sequence variants
sing denaturing high-performance liquid chromatography
DHPLC) (WAVE, Transgenomic, Omaha, Nebraska)
15). All samples with abnormal DHPLC elution profiles
ere characterized by direct DNA sequencing (ABI Prism
77; Applied Biosystems, Foster City, California) to deter-
ine the precise sequence variation present. Nonsynony-
ous variants were reconfirmed by sequencing from stock
NA samples. All candidate disease-associated mutations
ere searched for in 100 healthy black and 100 healthy
hite DNA samples (400 reference alleles) obtained from
oriell Laboratories (Camden, New Jersey) to exclude the
ariant as a common polymorphism.
tatistical analysis. Analysis of variance tests were used to
ssess differences between continuous variables, followed by
isher Protected Least Significant Difference post-hoc test-
ng for pairwise differences. Contingency tables or z-tests
ere used as appropriate to analyze nominal variables.
robability values  0.05 were considered statistically
Abbreviations and Acronyms
DHPLC  denaturing high-performance liquid
chromatography
DNA  deoxyribonucleic acid
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LVOTO  left ventricular outflow tract obstruction
LVWT  left ventricular wall thickness
MYBPC3  myosin binding protein C
MYH7  beta-myosin heavy chain
SCD  sudden cardiac deathignificant. cESULTS
linical analysis of cohort. This single institution cohort
omprising 389 unrelated patients (215 male) with HCM
as diagnosed at a mean age of 41.3  19 years. At
resentation to Mayo Clinic, 216 (55.5%) had cardiac
ymptoms, 120 (31%) had a family history of HCM, and 56
14%) had a SCD event in a first-degree relative. The mean
aximum LVWT was 21.5  7 mm, and mean peak
radient for left ventricular outflow tract obstruction
LVOTO) was 46.6  42 mm Hg. Of 389 patients, 297
76%) had resting, labile, or mid-cavitary obstruction; 161
41%) had undergone a surgical myectomy; and 60 (15%)
ad received an implantable cardioverter-defibrillator
ICD).
pectrum of MYBPC3 mutations. In this cohort, 46
ifferent MYBPC3 mutations were identified in 71 of 389
atients (18%). Thirteen of the identified mutations had
een published previously, and the remaining 33 (72%) were
ovel (Fig. 1, Table 1). Mutations were identified in 20 of
3 exons studied. Each of the novel mutations identified
as not found in the 400 reference alleles. Twenty-one
46%) of the mutations identified altered single amino acids
missense mutations), 15 (33%) were insertions or deletions
ausing a frameshift, 6 (13%) coded for premature stop
odons (nonsense mutations), 3 (7%) were putative splice
onor or acceptor site mutations located in the introns, and
(2%) was an in-frame deletion (Fig. 1, Table 1). No
tatistically significant difference in clinical phenotype was
ttributable to the specific type of MYBPC3 mutation
resent (i.e., missense vs. premature truncations resulting
rom frameshift and nonsense mutations [data not shown]).
In addition to the putative pathogenic mutations identi-
ed, 7 amino-acid altering variants in MYBPC3 were
dentified in patient samples as well as our 400 reference
lleles (Table 1). In addition, three such variants were
dentified in 5 individual patients (S236G, R326Q, and
896M), were not seen in our 400 reference alleles, but
ere previously reported as common polymorphisms with
llele frequencies0.5% (6). Therefore, these three variants
ere not considered pathogenic, and these five patients were
ot included in the MYBPC3-HCM subgroup.
henotype of MYBPC3-HCM. When patients with a
ingle mutation in MYBPC3 (n  63, excluding those
arboring multiple mutations in one or more genes) (Fig. 2)
ere compared with those patients with single mutations
nvolving the thick filament (MYH7 or light chains, n 
1), there were no statistically significant differences with
espect to age at diagnosis (37.6  15 years vs. 33.0  17
ears), LVWT (22.5  5 mm vs. 23.5  7 mm), frequency
f myectomy (35% vs. 56%), or frequency of ICD placement
29% vs. 21%) (Table 2). The phenotype ascribed to thick
lament-HCM is not affected by removal of individuals
ith mutations in one of the two genetic components of the
hick filament, namely mutations in the regulatory light
hain encoded by MYL2 (data not shown). Compared with
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November 2, 2004:1903–10 MYBPC3 and Compound Heterozygosity in HCMatients with thin filament mutations (alpha-actin, alpha-
ropomyosin, troponin-T, or troponin-I, n  13), patients
ith MYBPC3-HCM were not statistically different in
hese same clinical parameters (Table 2, Figs. 3 and 4).
ith regard to HCM morphology (resting obstruction,
abile obstruction, mid-cavitary obstruction, apical, and
onobstructive HCM), again, no statistically significant
ifferences were present between MYBPC3-HCM, thick
lament-HCM, thin filament-HCM, and multiple
utation-HCM (data not shown).
henotype of patients with no identified mutation. In
his cohort of 389 patients, 242 (62.2%) have no mutations
n the eight genes studied to date (Fig. 2). This subset of
atients (genotype negative) is significantly older at diagno-
is than patients with an identifiable sarcomere defect
igure 1. Schematic diagram of mutations identified in MYBPC3. Vertical
heir exonic location. *Novel mutation.genotype positive) (Table 2, Fig. 3). In fact, patients with penotype-negative HCM were older at diagnosis than even
hose with MYBPC3-HCM (45.4  19 years vs. 37.6  15
ears, p  0.003). These genotype-negative patients also
ave significantly less hypertrophy than patients with thick
lament or multiple mutations and trended toward less
ypertrophy than patients with MYBPC3-HCM (Table 2,
ig. 4).
henotype of patients with multiple sarcomeric muta-
ions. In all, 10 of 389 patients were identified with
ultiple sarcomeric mutations (i.e., compound heterozygos-
ty, 2.6% of total cohort, 7% of the genotyped subset) (Fig.
). One patient had mutations in MYH7 and troponin-T
R453C and Q191del, respectively), and one patient had
wo MYH7 mutations (R719Q plus T1513S). Multiple
YBPC3 mutations were identified in two patients (G5R
represent exons, and mutations identified in this cohort are indicated abovelineslus R502W, E258K plus A954fs/94); MYBPC3 and
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MYBPC3 and Compound Heterozygosity in HCM November 2, 2004:1903–10Table 1. Putative HCM-Causing Mutations and Nonpathogenic, Nonsynonymous
Polymorphisms Identified in MYBPC3
Mutation or
SNP # Exon Nucleotide Change Variant
Mutation Type
(Heterozygote Frequency
for Polymorphisms)†
1* 1 gggcgg G5R Missense mutation
2* 2 ag int-1 splice Splice mutation
3* 2 del gggcacacggc T59 fs/49 Frameshift mutation
4* 6 gtcctc V219L Missense mutation
5* 6 gtcatc V256I Missense mutation
6 6 gagaag E258K Missense mutation
7 7 ga int1 splice Splice mutation
8* 13 del c D389 fs/15 Frameshift mutation
9* 15 del tt I411 fs/0 Frameshift mutation
10* 16 cgccag R458H Missense mutation
11* 17 gggagg G490R Missense mutation
12 17 cggcag R495Q Missense mutation
13 17 cggtgg R502W Missense mutation
14 17 gaacaa E542Q Missense mutation
15* 18 del gt E546 fs/19 Frameshift mutation
16* 18 del ga C566 fs/3 Frameshift mutation
17* 19 gacgtc D604V Missense mutation
18* 19 gacaac D605N Missense mutation
19* 19 cctctt P609L Missense mutation
20 22 del c A698 fs/54 Frameshift mutation
21* 23 cgctgc R733C Missense mutation
22* 23 gacaac D770N Missense mutation
23* 24 ag int2 splice Splice mutation
24 24 ins g Q791 fs/40 Frameshift mutation
25* 24 tggcgg W792R Missense mutation
26* 24 del g P794 fs/26 Frameshift mutation
27 25 cgccac R810H Missense mutation
28* 25 del aag K811del Deletion mutation
29* 25 del atgcg W818 fs/11 Frameshift mutation
30* 25 ins t S830 fs/1 Frameshift mutation
31 25 gcgacg A833T Missense mutation
32* 25 gagtag E843X Truncation mutation
33* 25 tactag Y847X Truncation mutation
34* 25 del c A851 fs/26 Frameshift mutation
35* 25 ins t, ggctgc A851 fs/31 Frameshift mutation
36* 25 del g I852 fs/25 Frameshift mutation
37* 26 tggtga W890X Truncation mutation
38* 27 cgatga R943X Truncation mutation
39 27 del ct A954 fs/94 Frameshift mutation
40 27 caataa Q969X Truncation mutation
41* 28 caggag Q998E Missense mutation
42* 28 cagcgg Q998R Missense mutation
43* 29 ins aa G1041 fs/5 Frameshift mutation
44* 31 ttcatc F1113I Missense mutation
45* 31 tgctga C1124X Truncation mutation
46* 31 attact I1131T Missense mutation
1* 4 gtgatg V58M Polymorphism (11%)
2 6 acgggc S236G Polymorphism (20%)‡
3 12 cggcag R326Q Polymorphism (6%)‡
4* 13 cggtgg R382W Polymorphism (6%)
5* 15 ggtagt G416S Polymorphism (2%)
6* 17 gggagg G507R Polymorphism (4%)
7* 18 ctgatg L545M Polymorphism (1%)
8 26 gtgatg V896M Polymorphism (5%)‡
9 33 cagtag Q1233X Polymorphism (2%)
10* 33 dup gggggcatctatgtctgc GGIYVC Polymorphism (1%)
1248–1253dup
*Indicates a novel mutation or variant; †in 100 African American and 100 Caucasian deoxyribonucleic acid samples, unless
otherwise noted; ‡previously published frequency (6).
HCM  hypertrophic cardiomyopathy; SNP  single nucleotide polymorphism.
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November 2, 2004:1903–10 MYBPC3 and Compound Heterozygosity in HCMYH7 in two patients (D605N plus E894G, Q791fs/40
lus R694C); MYBPC3 and troponin-T in two patients
V256I plus R92W, A833T plus R286H); MYBPC3 and
roponin-I in one patient (R943X plus S166F); and
YBPC3 and -tropomyosin in one patient (F1113I plus
172T). These 10 patients were significantly younger at
iagnosis than any other subgroup, had the most hypertro-
hy, and had the highest incidence of myectomy and ICD
lacement, 3 of the 4 of which were placed due to the strong
amily history of SCD (Table 2, Figs. 3 and 4).
ISCUSSION
his study provides mutational analysis of the largest cohort
f unrelated patients derived from a single institution to
ate for the most common genetic cause of HCM seen in
his cohort, MYBPC3, and completes the comprehensive
utational analysis of the eight most common sarcomeric
ubtypes of HCM. In this cohort, MYBPC3-HCM was
tatistically indistinguishable from other sarcomeric causes
f HCM by clinical parameters of LVWT, LVOTO, or
ncidence of myectomy.
It was observed previously that MYBPC3 mutations were
ssociated with variable onset of disease and prognosis,
ncluding late-onset HCM and benign disease (7–9). In our
ohort, the age at diagnosis for MYBPC3 mutation carriers
as not statistically different than patients with thick
lament-HCM, thin filament-HCM, or genotype-negative
igure 2. Distribution of sarcomeric mutations in patients with hypertrop
ohort of 389 unrelated patients is indicated as n (%). Note that each geno
he “multiple mutations” subgroup.CM. Similarly, these unrelated MYBPC3-HCM patients gave not as yet experienced a more benign course than those
ith other HCM genotypes or those with genotype-
egative HCM, as there was no lower frequency of myec-
omy or ICD in these patients, or SCD among their
rst-degree relatives. Long-term follow-up of these patients
s necessary to establish disease course; however, this cross-
ectional study suggests, not surprisingly, that data from
inkage studies and large pedigrees may not always translate
o the individual patient in the clinical setting.
Previous studies have found significantly earlier disease
anifestations and a higher incidence of invasive procedures
n MYBPC3-HCM patients with mutations leading to
rotein truncation (frameshift or nonsense mutations) than
n their counterparts with missense or in-frame mutations
3,16). However, in our comparatively larger cohort, there
as no difference between these two groups for any clinical
ariable studied, likely due to a difference in study design. In
his study, only unrelated probands were included to avoid
kewing of the data by any single large pedigree manifesting
ither a benign or malignant disease course. Although large
edigree studies are clearly of crucial importance, the
urrent study design suggests that the findings from specific
edigrees cannot be extended to a series of unrelated
atients.
As perhaps anticipated, patients with multiple sarcomeric
utations had the most severe phenotype: youngest at
iagnosis, greater degree of hypertrophy, and highest sur-
ardiomyopathy. The relative frequency of each genotype identified in the
is exclusive of patients with multiple mutations, who are included only inhic cical intervention rate of the subgroups studied here. Over-
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MYBPC3 and Compound Heterozygosity in HCM November 2, 2004:1903–10ll, 2.6% of the entire cohort had evidence for compound
eterozygosity, and of those patients with an identified
arcomeric mutation, 7% were found to have two possible
utations. This finding is in accordance with a previous
nding of 5% frequency of complex genetic status in a
maller cohort (4). Because the high-throughput analysis of
ll HCM-associated genes has only recently become tech-
ically feasible, and the genetic cause for HCM remains to
e elucidated for 60% of our cohort, the relative risk
ssociated with multiple mutations remains to be deter-
ined.
Importantly, this study design includes only one proband
rom each pedigree, defined as the first member of a family
o be seen in our HCM clinic. Therefore, this study design
oes not provide direct information on mutation pen-
trance. In addition, because only individuals with clinical
isease (and not asymptomatic carriers) are included, the
enotype-phenotype correlations derived from this cohort
ay, in fact, overestimate the severity of disease ascribed to
ny particular genotype. However, our goal was to deter-
ine the frequency and phenotype of patients with
YBPC3-HCM seeking clinical evaluation, rather than
efining the degree of non-penetrance associated with a
articular HCM-causing genotype. In the subset of patients
eeking clinical attention for their clinical disease, we have
haracterized the phenotype of HCM caused by MYBPC3
utations.
The veracity with which these data represent the true
requency of MYBPC3 mutations and their phenotype in
CM may also be affected by bias present in this single-
able 2. Clinical Characteristics of Patients With Single, Multip
MYBPC3
Mutation
Thick Filamen
Mutation
umber of individuals 63 61
ale/female 41/22 25/36
ge at diagnosis
Mean (yrs) 37.6  15 33.0  17
Range 3.4–75.2 0.1–70.6
25 yrs, n (%) 50 (79%) 41 (67%)
resentation
Cardiac symptoms, n (%) 37 (59%) 30 (49%)
amily history*
HCM, n (%) 28 (44%) 27 (44%)
SCD, n (%) 13 (21%) 11 (18%)
chocardiography
LVWT (mm) 22.5  5 23.5  7
Severe hypertrophy†, n (%) 4 (6%) 9 (15%)
Peak LVOT gradient (mm Hg) 41.4  38 52.3  46
30 mm Hg at rest, n (%) 31 (49%) 36 (59%)
reatment
Myotomy/myectomy, n (%) 22 (35%) 34 (56%)
PM, n (%) 12 (19%) 13 (21%)
Myectomy or PM, n (%) 25 (40%) 37 (61%)
ICD, n (%) 18 (29%) 13 (21%)
o significant differences were defined between MYBPC3-HCM and thick filament
ANOVA  analysis of variance; HCM  hypertrophic cardiomyopathy; ICD 
eft ventricular wall thickness; MYBPC3  myosin binding protein C; PM  perman
egulatory myosin light chain; thin filament  troponin-T, troponin-I, -tropomyonstitution cohort. As a tertiary referral center known for murgical treatment of HCM, patients with obstructive dis-
ase treated by myectomy are overrepresented. However, in
ther clinical parameters, this cohort is similar to unselected
egional center patients (17). In previous studies of MYH7
utations in HCM, we found no difference in mutation
requency in regional (Minnesota, Wisconsin, and Iowa
esidents) versus non-regional HCM patients in our cohort
espite the fact that the non-regional HCM patients had a
reater degree of obstruction and a higher incidence of
yectomy (14). Similarly, in this cohort, there were no
tatistically significant differences in the frequency and
henotype of mutations in MYBPC3 in regional versus
on-regional patients (data not shown). In addition, it is
ossible that statistically significant differences do exist
etween genotyped subgroups, but are not apparent due to
nsufficient numbers of patients in each group. Future
eta-analysis studies pooling the data from this and addi-
ional published genotyped cohorts may provide sufficient
ower to discern subtle differences between genotypes.
owever, from this cohort, it is apparent that there is a
road spectrum of clinical presentation in sarcomeric
CM, which may limit the clinical relevance of such
ndings.
Our estimation of MYBPC3 mutation frequency is de-
endent upon the sensitivity of our mutation detection
latform (DHPLC), the correct assignment of mutations as
athogenic, and the exclusion of related individuals from
ur cohort. The published sensitivity for DHPLC is estab-
ished as 95%, and, for HCM mutation screening, 100%
ensitivity has been reported (18–21). Regarding assign-
No Sarcomeric Mutations
Thin Filament
Mutation
Multiple
Mutations
No Sarcomeric
Mutation
ANOVA
p Value
13 10 242
10/3 5/5 134/108 0.04
42.9  16 20.7  11 45.4  19 0.0001
22.6–72.5 0.2–37.4 0.0–89.5
12 (92%) 3 (30%) 202 (83%) 0.0001
10 (77%) 4 (40%) 134 (55%) 0.08
5 (38%) 5 (50%) 55 (23%) 0.01
3 (23%) 2 (20%) 27 (11%) 0.35
21.5  4 25.2  12 20.8  6 0.01
0 (0%) 2 (20%) 14 (6%) 0.07
34.9  42 46.3  44 47.3  42 0.60
5 (38%) 6 (60%) 128 (53%) 0.79
3 (23%) 6 (60%) 95 (39%) 0.04
2 (15%) 0 (0%) 40 (17%) 0.55
4 (31%) 6 (60%) 117 (48%) 0.10
2 (15%) 4 (40%) 23 (10%) 0.003
subsets. *In a first degree relative; †LVWT 30 mm.
ntable cardioverter-defibrillator; LVOT  left ventricular outflow tract; LVWT 
cemaker; SCD  sudden cardiac death; thick filament  -myosin heavy chain and
d -actin.le, or
t
-HCM
implaent of pathogenic mutations, every mutation identified in
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November 2, 2004:1903–10 MYBPC3 and Compound Heterozygosity in HCMhis study is not present in 400 reference alleles (200 from
thnically matched Caucasian Americans, and 200 from
thnically diverse African Americans) and is not a reported
olymorphism. Each variant alters a residue that is con-
erved across species and causes a change in the amino-acid
equence of the protein product, whether by substitution,
runcation, or frameshift. The three variants identified in
he introns occur within the invariant splice donor or
cceptor sites within two nucleotides of the exon boundary.
ue to the substantial size of the genotype-positive cohort,
o-segregation of each mutation has not yet been deter-
ined. Such co-segregation data would provide further
vidence that each mutation is correctly assigned, and this is
he subject of ongoing investigation. It is of interest to note
hat seven nonsynonymous polymorphisms were identified
n our panel of 400 reference alleles, one of which (Q1233X)
as previously reported as an HCM-pathogenic mutation,
ased on co-segregation within a family and absence from
00 reference alleles (3). This finding highlights the diffi-
ulty in assessing whether a sequence variant identified is
ruly the pathogenic mutation for HCM, and the impor-
ance of adequate controls. Ongoing structure-function
tudies of MYBPC3 are needed to characterize the function
f this protein to assist in the assignment of mutations as
ndependently pathogenic (HCM-causing) mutations, bio-
ogically relevant susceptibility variants, or irrelevant non-
ynonymous polymorphisms.
Finally, clinical assessment was used to exclude relatedness
o three degrees. If more distantly related individuals with or
ithout MYBPC3 mutations have been included in this cohort,
ur estimation of MYBPC3 mutation frequency would be
igure 3. Age at diagnosis by genotyped subsets. Genotyped hypertrophic
ardiomyopathy patients are grouped on the X-axis, and age at diagnosis is
ndicated on the Y-axis. Error bars  standard deviation. Unless noted, all
ther pairwise comparisons were not statistically significant. Thick filament
beta-myosin heavy chain and regulatory myosin light chain; thin
lament  troponin-T, troponin-I, alpha-tropomyosin, and alpha-actin.
p  0.003; **p  0.0001; ***p  0.05 vs. all other subgroups.alsely high or low, respectively. However, using our clinical mnalysis, we were able to exclude 45 related individuals before
nalysis, proving the efficacy of the method. In addition, due to
he large size of the cohort and subset with MYBPC3 muta-
ions, the influence of concealed relatives on the genotype-
henotype observations would be minimal.
onclusions. This study establishes MYBPC3 as the most
ommon genetic cause for HCM in our tertiary referral
enter, with mutations found in 18% of patients with
CM. Patients with MYBPC3 mutations were diagnosed at
younger age than those without sarcomeric mutations.
lthough prediction of the causative mutation based on age
f onset or degree of hypertrophy has been suggested,
atients with single MYBPC3 mutations are not diagnosed
ater or with less severe hypertrophy than those with MYH7
utations, making such predictions impossible. Patients
ith multiple mutations have the most severe disease,
uggesting that for individuals presenting early in life with
xtreme hypertrophy and a positive family history, the
earch for additional mutations should continue after the
dentification of an initial putative HCM-causing defect.
atients with no identifiable sarcomeric mutation were
ignificantly older than those with sarcomeric mutations,
uggesting an alternate genetic mechanism for HCM in
lderly patients.
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